Effects of calcitriol on bone mineral density in patients treated with esomeprazole

Figures & data

Table 1. Characteristics of study populations.

Variables	Controlled group (n = 193)	Supplemented group (n = 193)	p
Age (years)	43.8 ± 5.6	44.3 ± 4.1	0.187
Female (%)	68 (35.2)	71 (36.8)	0.334
Current smoking (%)	40 (20.7)	38 (19.7)	0.078
Glucocorticoid used history (%)	8 (4.1)	9 (4.7)	0.165
Fracture history (%)	4 (2.1)	6 (3.1)	0.263
Post-menopause (%)	11 (5.7)	13 (6.7)	0.087
Body mass index (kg/m^2)	21.8 ± 2.4	21.4 ± 2.1	0.198
Past calcium supplement (%)	42 (21.8)	45 (23.3)	0.336
Hemoglobin level (g/L)	125.6 ± 8.1	127.4 ± 10.4	0.264

Table 2. Comparisons of mean BMD T score.

Mean BMD T score	Controlled group	Supplemented group	p
Femoral neck  (before administration)	−1.25 ± 0.08	−1.25 ± 0.05	0.244
Femoral neck  (after termination)	−1.28 ± 0.06	−1.26 ± 0.03	0.108
p	0.084	0.308

Table 3. Comparisons of indices.

Indices	Controlled group	Supplemented group	p
Serum calcium (mmol/L, before administration)	2.08 ± 0.04	2.07 ± 0.05	0.365
Serum calcium (mmol/L, after termination)	2.01 ± 0.05	2.05 ± 0.03	0.073
Serum CTX (pg/mL, before administration)	355.63 ± 46.32	361.40 ± 52.43	0.427
Serum CTX (pg/mL, after termination)	373.15 ± 50.23	366.57 ± 43.71	0.086
Serum ALP (U/L, before administration)	49.65 ± 7.07	50.26 ± 12.24	0.083
Serum ALP (U/L, after termination)	52.23 ± 10.45	50.47 ± 9.32	0.075